Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - A pilot study

Gynecologic and Obstetric Investigation

Volumn 55, Issue 1, 2003, Pages 25-31

  Suh Burgmann, Elizabeth ^a,b   Sivret, Julia ^a   Duska, Linda R ^a   Del Carmen, Marcella ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Cervix; Chemoprevention; Dehydroepiandrosterone; Dysplasia; Neoplasia; Preinvasive cervical disease

Indexed keywords

ANDROSTENEDIONE; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ACNE; ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; COLPOSCOPY; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSURIA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; LONG TERM CARE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; UTERINE CERVIX DYSPLASIA;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PILOT PROJECTS; TESTOSTERONE; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 0037219523     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068953     Document Type: Article

References (35)

1. Kurman RJ, Hensen DE, Herbst AL, Noller KL, Schiffman MH: Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute workshop. JAMA 1994;271:1866-1869.
2. Ostor AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993;12:186-192.
3. Cohn JA, Gagnon S, Spence MR, Harrison DD, Kluzak TR, Langenberg P, Brinson C, Stein A, Hellinger J: Cervical Disease Study Group of the American Foundation for AIDS Research Community-Based Clinical Trials Network. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Am J Obstet Gynecol 2001;184:322-330.
4. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA: Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000;88:2283-2289.
5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.
6. Poppe WA, Drijkoningen M, Ide PS, Lauweryns JM, Van Assche FA: Langerhans' cells and L1 antigen expression in normal and abnormal squamous epithelium of the cervical transformation zone. Gynecol Obstet Invest 1996;41:207-213.
7. Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA: Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. Gynecol Obstet Invest 1995;39:34-38.
8. American Social Health Association: Sexually Transmitted Diseases in America: How many cases and at what cost? Research Triangle Park, American Social Health Association, 1998.
9. Seigal J: The economic burden of sexually transmitted diseases in the United States; in Holmes K, Mardh P, Sparling P et al (eds): Sexually Transmitted Diseases, ed 3. New York, McGraw-Hill, 1999, pp 1367-1380.
10. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA et al: Strategy and planning for chemopreventive drug development: Clinical Development Plans II. J Cell Biochem 1996;26(suppl):54-71.
11. Canning MO, Grotenhuis K, de Wit HJ, Drexhage HA: Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells. Eur J Endocrinol 2000;143:687-695.
12. Loria RM, Padgett DA: Mobilization of cutaneous immunity for systemic protection against infections. Ann NY Acad Sci 1992;650:363-366.
13. Pashko LL, Hard GC, Rovito RJ, Williams JR, Sobel EL, Schwartz AG: Dehydroepiandrosterone and 3β-methyladrost-5-en-17-one inhibit 7,12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas in mice. Cancer Res 1985;45:164-166.
14. Schwartz AG: Inhibition of spontaneous breast cancer formation in female C3H mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979;39:1129-1133.
15. Schwartz AG, Tannen RH: Inhibition of 7,12-dimethylbenz(a)anthracene- and urethane-induced lung adenomas in A/J mice by long-term treatment with dehydroepiandrosterone. Carcinogenesis 1981;2:1335-1337.
16. Nyce JW, Magee PN, Hard GC, Schwartz AG: Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. Carcinogenesis 1984;5:57-62.
17. Moore MA, Thamavit W, Tsuda H, Sato K, Ichibara A, Ito N: Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propylnitrosamine initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis 1986;7:311-316.
18. Weber E, Moore MA, Bannasch P: Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitroso-morpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepian-drosterone. Carcinogenesis 1988;9:1191-1195.
19. Melvin WS, Bosos LG, Muscarella P et al: Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery 1997;15:392-397.
20. Kawai S, Yahata N, Nishida S, Nagai K, Mizushima Y: Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. Anticancer Res 1995;15:427-431.
21. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE et al: Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999;59:3084-3099.
22. Casson PR, Straughn AB, Umstod ES et al: Delivery of dehydroepiandrosterone to premenopausal women: Effects of micronization and nonoral administration. Am J Obstet Gynecol 1996;174:649-653.
23. Verthelyi D, Klinman DM: Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000;100:384-390.
24. Cheng GF, Tseng J: Regulation of murine interleukin-10 production by dehydroepiandrosterone. J Interferon Cytokine Res 2000;20:471-478.
25. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S et al: Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 2000;74:4729-4737.
26. Casson, PR, Andersen RN, Herod HG, Stentz FB, Straughn AB et al: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993;169:1536-1539.
27. Daynes RA, Dudley DJ, Araneo BA: Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin-2 synthesis by helper T cells. Eur J Immunol 1990;20:793-802.
28. Suzuki T, Suzuki N, Daynes RA, Engleman EG: Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991;61:202-211.
29. Khorram O, Vu L, Yen SSC: Activation of immune function by dehydroepiandrosterone in age-advanced men. J Gerontol A Biol Sci Med Sci 1997;52:M1-M7.
30. Clerici M, Galli M, Bosis S, Gervasoni C, Moroni M, Norbiato G:Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann NY Acad Sci 2000;917:956-961.
31. Ciolino HP, Yeh GC: The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism. J Biol Chem 1999;274:35186-190.
32. Mortola JF, Yen SSC: The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in post-menopausal women. J Clin Endocrinol Metab 1990;71:696-704.
33. Van Vollenhoven RF, Engleman EG, McGuire JF: Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-1831.
34. Holowaty P, Miller AB, Rohan T, To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-258.
35. Hording U, Junge J, Rygaard C, Lundvall F: Management of low-grade CIN: Follow-up or treatment. Eur J Obstet Gynecol Reprod Biol 1995;62:49-52.